Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2020

View Archived Issues

Sosei Heptares identifies antiviral small molecules for COVID-19

iSD and Biogen establish strategic research collaboration for ISD-017 for SLE

Further positive data from phase II study of GV-1001 in Alzheimer's disease

Positive topline data from phase IIb study of ARQ-154 in scalp and body psoriasis

Ascentage receives approval for phase Ib/II studies of APG-2575 in China

Onconova files IND application with FDA for ON-123300

Positive topline data from phase II OLE study of Tesomet in hypothalamic obesity

Chinese researchers patent compounds for liver diseases

ViiV Healthcare divulges new HIV1 inhibitors

AiCuris synthesizes HBV capsid assembly inhibitors

European researchers discover new NR1I3 agonists

New antibodies for COVID-19 presented by University of Pittsburgh

OBI Pharma provides promising phase I data for OBI-833

Phase II data presented for saroglitazar in patients with PBC

BCL6 degrader works via combine and conquer strategy

Targovax reports 18-month data from phase I/II study of ONCOS-102 in mesothelioma

Late events dog gene therapy

Bad seeds get an early start in AD

Phase II interim analysis of HER-Vaxx in advanced gastric cancer shows improved OS

Treatment begins in phase II/III study of Evgen's SFX-01 for ARDS

KN-046 plus KN-026 in HER2-positive solid tumors well tolerated, shows antitumoral activity

FDA approves Zokinvy for Hutchinson-Gilford progeria syndrome and progeroid laminopathies

First cohort data from phase I study of GRAd-COV2 show immune responses

Phase I/II study of SBI-101 for severe COVID-19 begins dosing

Clazosentan reduces all-cause morbidity and mortality post-aSAH in Japanese registration trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...